Best Grants for HIV / AIDS in Wyoming

Students and recent graduates in Wyoming planning unpaid summer 2025 internships in HIV/AIDS research, advocacy, or services can apply for Point Foundation’s Kadel & Gerhardt Internships, with awards up to Up to US $7,000. Eligible applicants must be enrolled in, or within a year of completing, a degree-seeking program at a US-accredited institution.

Research institutions and organizations conducting HIV/AIDS research in Wyoming and nationwide can access funding through the US Dept. of Health & Human Services: National Institutes of Health. Grants from NIH help Wyoming HIV / AIDS programs join the Centers for AIDS Research network, supporting infrastructure, multidisciplinary collaborations, and mentoring for early-career investigators working to end the HIV epidemic domestically.

Research institutions and multidisciplinary scientific teams in Wyoming and nationwide can apply for US Dept. of Health & Human Services: National Institutes of Health support to establish Centers for Structural Biology of HIV and other infectious diseases. Funding supports advanced structural biology research, technology development, and training focused on molecular targets for new diagnostics and treatments.

Grants from the National Institutes of Health help Wyoming organizations conducting pilot or feasibility studies on substance use and HIV prevention, treatment, or services research. Eligible projects may develop or adapt interventions, test acceptability and feasibility, or create measures and methods for future trials, engaging policymakers, practitioners, and people with lived experience across the U.S. territories and states.

Early-career investigators conducting HIV/AIDS research on chronic conditions, coinfections, and comorbidities can apply for national funding that includes Wyoming. Grants from the National Institutes of Health help researchers pursue innovative, transformative studies, especially in pediatric and maternal HIV prevention and treatment, including projects leveraging mathematics, engineering, computer science, or AI approaches.

Wyoming HIV / AIDS researchers and institutions can access funding through the National Institutes of Health to study how HIV immunotherapies affect central nervous system outcomes. This R21/R33 opportunity supports biphasic research on CNS HIV persistence, mechanisms, benefits, and risks, aiming to improve long-term neurologic and cognitive outcomes in people with HIV. Awards up to US $2,000,000.

Research institutions and clinical organizations conducting HIV and HIV-associated disease clinical trials can apply for National Institutes of Health support, including work based in Wyoming. Grants from NIH help HIV / AIDS programs operate Clinical Trials Units with administrative hubs and domestic or international research sites to run multiple randomized studies and implementation research.

Research institutions and clinical trial networks conducting HIV/AIDS prevention, treatment, and implementation research in Wyoming and nationwide can access funding through the National Institutes of Health to serve as Statistical and Data Management Centers. Awards support leadership in trial design, data collection and monitoring, data quality and integration, regulatory compliance, and harmonized statistical and data practices.

Research institutions and clinical laboratories working on HIV/AIDS clinical trials can apply for National Institutes of Health support to serve as Laboratory Centers within HIV Clinical Trials Networks, including work impacting Wyoming. Awards fund laboratory infrastructure, testing, data systems, and assay development to support HIV prevention, treatment, and implementation research across participating sites.

Focused on HIV/AIDS clinical research, the National Institutes of Health invites Wyoming research institutions and clinical trial networks to lead Leadership and Operations Centers advancing HIV prevention, treatment, and implementation studies. Eligible centers will set research agendas on therapeutics, biomedical prevention, and immune-based strategies to help end the HIV epidemic.

Public health agencies and research-focused organizations in Wyoming working on HIV/AIDS surveillance and prevention can apply for the National HIV Behavioral Surveillance program, funded by the Centers for Disease Control and Prevention. Grants support ongoing bio-behavioral data collection, HIV testing, linkage to care, and evaluation of HIV prevention strategies among disproportionately affected populations across U.S. jurisdictions.

Research institutions working on substance use, addiction, and HIV can apply for core center funding to build transformative, collaborative research hubs in Wyoming and nationwide. Focused on advancing addiction and HIV science, the National Institutes of Health supports centers that integrate existing projects, share resources, and develop early-career investigators.

Research institutions conducting HIV/AIDS studies in the U.S., including Wyoming, can apply for US $212,004 - US $2,725,311 from the National Institutes of Health to develop and manage specific pathogen free (SPF) in vivo models and human new approach methodologies. Funding supports NAMs triage services, human in vitro testing support, and high-quality SPF colony operations.

Research institutions conducting interdisciplinary HIV/AIDS mental health research, including in Wyoming and other eligible U.S. jurisdictions, can access funding through the National Institutes of Health to establish or expand AIDS Research Centers. Grants support coordinated centers advancing basic, neuro-HIV, behavioral, clinical, translational, implementation science, and data science projects through strong collaborations and alignment with national HIV/AIDS strategies.

HIV/AIDS planning bodies and Ryan White HIV/AIDS Program Parts A and B recipients can receive funding to improve integrated HIV prevention and care planning across the U.S., including Wyoming. Focused on HIV/AIDS, the Health Resources & Services Administration offers tools, training, and technical assistance to maximize resources and strengthen HIV care and treatment systems, with awards up to US $700,000.

The AIDS Drug Assistance Program (ADAP) Emergency Relief Funds aim to provide essential funding to states and territories. This initiative focuses on preventing, reducing, or eliminating waiting lists for ADAP services, ensuring timely access to necessary medications and support for individuals living with HIV/AIDS. This program addresses critical funding shortfalls, enhancing the healthcare infrastructure and improving health outcomes in affected communities.

The Ryan White HIV/AIDS Program Part C Capacity Development Program aims to enhance the capabilities of community-based organizations, focusing on improving health outcomes and decreasing HIV transmission. This initiative supports individuals who have not yet accessed regular HIV care, emphasizing innovative care solutions and infrastructure development to address these critical needs.

The HIV Care Grant Program, funded by the US HHS: Health Resources & Services Administration (HRSA), aims to enhance access to high-quality HIV care and treatment for low-income individuals. This initiative supports states and territories in developing comprehensive systems to address the needs of those living with HIV. By providing essential resources, the program seeks to improve health outcomes and ensure that vulnerable populations receive the necessary support and services.

The Ryan White HIV/AIDS Program Part B Supplemental Grant aims to provide essential funding to support HIV care and treatment services across states and territories. This program supplements existing formula-based funding from the RWHAP Part B and ADAP, improving access to necessary resources for those affected by HIV/AIDS. By enhancing support structures, it addresses critical healthcare needs, ensuring better health outcomes for vulnerable populations.

The HIV Care Grant Program aims to enhance access to comprehensive, high-quality HIV care and treatment for low-income individuals in Pacific Island territories. Funded by the US HHS: Health Resources & Services Administration (HRSA), this initiative supports states and territories in developing effective systems of care, ensuring that those affected by HIV receive the necessary treatment and support to improve health outcomes.

This funding opportunity aims to enhance a web-based ordering portal for distributing 1.5 million HIV and STI self-tests to high-burden communities. By optimizing access to these self-tests, the initiative seeks to raise awareness, prevent new infections, and improve the health outcomes of users, thereby contributing to better overall public health and wellbeing.

This project aims to enhance health outcomes for women living with HIV in the South by integrating HIV care with comprehensive women's health services through coordinated Clinic and Community Collaboratives. By funding organizations to implement targeted strategies such as culturally responsive services and learning collaboratives, the initiative seeks to improve access to essential health services, increase the number of women initiating rapid ART, and foster sustainable healthcare models that address the unique needs of this population.

The Ryan White HIV/AIDS Program Part D provides supplemental funding aimed at enhancing the infrastructure and capacity of organizations to deliver high-quality, family-centered HIV care services. This initiative focuses on two key areas: HIV Care Innovation and Infrastructure Development, ensuring improved access to essential services for women, infants, children, and youth affected by HIV.

The Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Training and Technical Assistance aims to enhance the capacity of ADAPs. By providing essential tools and expert guidance, the program seeks to improve health outcomes for individuals living with HIV in an evolving healthcare landscape. This initiative is funded by the US HHS through the Health Resources & Services Administration, ensuring support and resources are effectively allocated to meet the needs of vulnerable populations.

Gilead Sciences

At Gilead, we are relentlessly committed to advancing transformative therapies for the most serious diseases, delivering an exponentially positive impact on health.

For more than three decades, we have combined scientific rigor with a deep sense of purpose to improve health outcomes and reimagine care. Our work spans more than 35 countries with a focus on three therapeutic areas: virology, oncology, and inflammation, where unmet medical needs remain greatest.

From individual patients to whole populations, we’re committed to delivering healthier futures for people and communities worldwide.

Our Mission: To discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

HIV Prevention NOVA 2026

Program Description

Gilead Sciences invites research proposals that advance the evidence base for innovative and scalable models of delivery for long-acting (LA) HIV pre-exposure prophylaxis (PrEP) in the United States.

This Topic of Interest (TOI) is focused on care delivery models implemented in non-traditional settings, defined as clinical and non-clinical environments where PrEP services are not routinely provided. Emphasis is placed on approaches that reflect real-life practice and address gaps in current PrEP delivery infrastructure.

Persistent inequities in PrEP uptake in the U.S. suggest that expanding availability within traditional clinical settings alone is unlikely to reach all populations with unmet PrEP need.1,2 Rigorous implementation studies in non-traditional settings where PrEP services are not routinely provided are needed to evaluate whether these models can reduce access barriers and improve equitable reach among individuals who may benefit from PrEP.2,3,4

The goal of this TOI is to generate practical, decision-relevant evidence that informs how LA PrEP can be implemented, scaled, and sustained in real-life U.S. settings.

About Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Who we are and our impact

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

HIV, AIDS, and prevention

Help with healthcare costs for HIV, AIDS, and prevention

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

About the disease

HIV, also known as human immunodeficiency virus or acquired immunodeficiency syndrome, is a virus that attacks the immune system. When left untreated, it can develop into AIDS. HIV is a chronic disease that affects the immune system.

The Ittleson Foundation, established in 1932, focuses on enhancing mental health, AIDS prevention, and environmental initiatives. It funds not-for-profit organizations aiming to improve public policy and the lives of citizens. The Foundation is particularly interested in innovative projects addressing mental health stigma, advancing preventative efforts, and supporting underserved populations. While it funds new initiatives, it does not typically support capital projects, endowments, or direct service programs outside New York City.